Study |
Year |
Cohort |
Nº cases |
Intervention |
End Point |
RR |
Result |
PHS (Gann) |
1993 |
Healthy |
22071 |
325 mg every other day vs. placebo |
CCR
incidence |
1.15 0.80-1.65 |
Negative |
PHS (Stürmer) |
1998 |
Healthy |
22071 |
325 mg every other day vs. placebo |
CCR
incidence |
1.03
0.83-1.28 |
Negative |
Cook et al. [10] |
2004 |
Healthy |
39876 |
100 mg every other day |
CCR
incidence |
0.97
0.77-1.24 |
Negative |
Baron et al. [11] |
2003 |
Prior adenoma |
1121 |
81 mg vs. 325 mg daily vs. placebo |
Adenomas
incidence |
0.81
0.69-0.96 |
Positive for 81 mg arm |
Sandler at al. [13] |
2003 |
Prior CCR |
635 |
325 mg daily vs. placebo |
Adenomas
incidence |
0.65
0.46-0.91 |
Positive |
APPAC |
2003 |
Prior adenoma |
272 |
160 mg vs. 325 mg vs. placebo |
Adenomas
incidence |
0.73
0.52-1.04 |
Negative in
global |
|